Vol. 5 No. 8 (2025)
Reimbursement Reviews

Pemigatinib (Pemazyre)

decorative image of the issue cover

Published August 25, 2025

Key Messages

  • Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses Pemigatinib (Pemazyre), tablets, 4.5 mg, 9 mg, and 13.5 mg, oral.
  • Indication: For the treatment of adults with previously treated, unresectable, locally advanced or metastatic CCA with a FGFR2 fusion or other rearrangement.